Top in endocrinology: Nonalcoholic fatty liver disease in patients with obesity, diabetes

In a recent study, adults with overweight or obesity and nonalcoholic fatty liver disease who received daily subcutaneous growth hormone had a significant reduction in liver fat and inflammation compared with those who received placebo.

Laura Dichtel, MD, MHS, an assistant professor in the neuroendocrine unit of Massachusetts General Hospital and Harvard Medical School, said the findings may inform future research investigating potential therapeutic options for nonalcoholic fatty liver disease (NAFLD). It was the top story in endocrinology last week.

Another top story was about an association between thyroid hormone levels and NAFLD in patients with type 2 diabetes. Researchers said the study results suggest that changes in thyroid hormone levels should be routinely assessed in patients with type 2 diabetes to help predict prognosis.

Read these and more top stories in endocrinology below:

Growth hormone reduces liver fat, inflammation in adults with NAFLD

Adults with overweight or obesity and NAFLD had a significant reduction in liver fat and inflammation with daily subcutaneous growth hormone administration, according to a speaker. Read more.

Thyroid hormone levels linked to liver fibrosis in type 2 diabetes

Among patients with type 2 diabetes and normal thyroid function, thyroid hormone levels were linked to NAFLD, suggesting assessment of these hormones might be beneficial for disease prevention and treatment. Read more.

Artificial intelligence may be used to identify benign thyroid nodules

An ultrasound-based artificial intelligence classifier of thyroid nodules identified benign nodules with sensitivity similar to fine-needle aspiration, according to data presented at ENDO 2022. Read more.

Romosozumab improves BMD, reduces fracture risk in women with osteoporosis and CKD

Evenity (romosozumab, Amgen) improved bone mineral density at the lumbar spine, total hip and femoral neck, and reduced the relative risk for fractures in women with osteoporosis and mild-to-moderate chronic kidney disease, according to study data. Read more.

Adverse pregnancy outcomes rising with gestational diabetes

From 2014 to 2020 in the United States, the overall rate of multiple adverse pregnancy outcomes rose for pregnant individuals with gestational diabetes, and rates of specific adverse outcomes varied by race and ethnicity, according to data. Read more.